ArticleAntimicrobial agents and chemotherapy2013
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Acanthamoeba Keratitis Management and Prognostic Factors: A Systematic Review.Journal of clinical medicine · 2025Review
- Effects of In Vitro Combination of Nitric Oxide Donors and Hypochlorite on Acanthamoeba castellanii Viability.Translational vision science & technology · 2023Article
- Synergistic Hypolipidemic Effects and Mechanisms of Phytochemicals: A Review.Foods (Basel, Switzerland) · 2022Review
- Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process inAntibiotics (Basel, Switzerland) · 2022Article
- Article
- In Vitro Effect of Pitavastatin and Its Synergistic Activity with Isavuconazole againstPathogens (Basel, Switzerland) · 2020Article
- Drug Discovery againstPathogens (Basel, Switzerland) · 2020Review
- Acanthamoeba encephalitis in immunocompetent hosts: A report of two cases.Journal of family medicine and primary care · 2020Article
- In Vitro Activity of Statins againstPathogens (Basel, Switzerland) · 2019Article
- Article
- Statins Perturb GMolecular pharmacology · 2019Article
- G418 induces programmed cell death in Acanthamoeba through the elevation of intracellular calcium and cytochrome c translocation.Parasitology research · 2019Article
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- Amoebicidal Activity of Caffeine and Maslinic Acid by the Induction of Programmed Cell Death in Acanthamoeba.Antimicrobial agents and chemotherapy · 2017Article
- Statins and voriconazole induce programmed cell death in Acanthamoeba castellanii.Antimicrobial agents and chemotherapy · 2015Article
- An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment.Parasite (Paris, France) · 2015Review
- Evaluation of Acanthamoeba myosin-IC as a potential therapeutic target.Antimicrobial agents and chemotherapy · 2014Article
- Antihyperlipidemic effects of apple peel extract in high-fat diet-induced hyperlipidemic rats.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acanthamoeba is an opportunistic pathogen in humans, whose infections most commonly manifest as Acanthamoeba keratitis or, more rarely, granulomatous amoebic encephalitis. Although there are many therapeutic options for the treatment of Acanthamoeba, they are generally lengthy and/or have limited efficacy. Therefore, there is a requirement for the identification, validation, and development of novel therapeutic targets against these pathogens. Recently, RNA interference (RNAi) has been widely used for these validation purposes and has proven to be a powerful tool for Acanthamoeba therapeutics. Ergosterol is one of the major sterols in the membrane of Acanthamoeba. 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, one of the precursors for the production of cholesterol in humans and ergosterol in plants, fungi, and protozoa. Statins are compounds which inhibit this enzyme and so are promising as chemotherapeutics. In order to validate whether this enzyme could be an interesting therapeutic target in Acanthamoeba, small interfering RNAs (siRNAs) against HMG-CoA were developed and used to evaluate the effects induced by the inhibition of Acanthamoeba HMG-CoA. It was found that HMG-CoA is a potential drug target in these pathogenic free-living amoebae, and various statins were evaluated in vitro against three clinical strains of Acanthamoeba by using a colorimetric assay, showing important activities against the tested strains. We conclude that the targeting of HMG-CoA and Acanthamoeba treatment using statins is a novel powerful treatment option against Acanthamoeba species in human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.